Thu, Mar 5, 2015, 11:48 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Eli Lilly and Company Message Board

canstic1 5 posts  |  Last Activity: Jan 5, 2015 5:45 PM Member since: Jul 13, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • canstic1 canstic1 Jan 5, 2015 5:45 PM Flag

    The deal with Orientech China, which is now approved by the China FDA is for sale of eight (8) BSD-2000's per year at a MINIMUM. They will most likely buy more. The deal to Taiwan calls for sale of 5 units per year MINIMUM, and they will most likely buy more. South Korea has a deal for another 5 per year, the approval in SK is still pending, and expected this year.

    We are now in the Q2 of fiscal year 2015 for BSDM. AT A MINIMUM, for this new fiscal year there will be 13 BSD-2000's sold, guaranteed to China(8) and Taiwan(5). BSDM has never sold 13 BSD-2000's in a single year , ever!

    These machines sell for $350,000 to over $1 million depending on how they are outfitted. That means at a minimum, and I stress MINIMUM, there will be $5 million in sales of BSD-2000's in fiscal year 2015.

    ADD in the sales of MicroThermX and replaceable antennas, and the MINIMUM sales I can possibly see occuring in fiscal 2015 is at least $10 million. BSDM has never had $10,000,000 in sales EVER

    And the stock is 40 cents? The historical low?

    What about GROWTH IN SALES? Factor that in? More likely BSDM will be pushing 20 million in sales than 10 million in fiscal 2015. IMHO.

    And also note that those contracts signed in China and Taiwan are 5 year deals. Those sales minimums repeat every year for 5 years. Also there is no debt in this company. Nothing. They do not owe one penny and do not need to service any debt. It will be very easy to turn the corner to profitablility now that BSD-2000's are starting to ship to Asia. Terumo will also be selling at a much higher rate this year as the MicroThermX ablation system gains traction in their 100 country territory.

    About Terumo Corporation

    A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology.

    And of course, one needs to add in U.S. sales of both hyperthermia and ablation devices. Those are not accounted for in the above numbers.

    Fiscal 2015 which began in September 2014, will be a record year in sales for BSDM, in my opinion. The facts all point directly to a record year.

  • canstic1 canstic1 Dec 22, 2014 5:53 PM Flag

    The deal with Orientech China, which is now approved by the China FDA is for sale of eight (8) BSD-2000's per year at a MINIMUM. They will most likely buy more. The deal to Taiwan calls for sale of 5 units per year MINIMUM, and they will most likely buy more. South Korea has a deal for another 5 per year, the approval in SK is still pending, and expected this year.

    We are now in the Q2 of fiscal year 2015 for BSDM. AT A MINIMUM, for this new fiscal year there will be 13 BSD-2000's sold, guaranteed to China(8) and Taiwan(5). BSDM has never sold 13 BSD-2000's in a single year , ever!

    These machines sell for $350,000 to over $1 million depending on how they are outfitted. That means at a minimum, and I stress MINIMUM, there will be $5 million in sales of BSD-2000's in fiscal year 2015.

    ADD in the sales of MicroThermX and replaceable antennas, and the MINIMUM sales I can possibly see occuring in fiscal 2015 is at least $10 million. BSDM has never had $10,000,000 in sales EVER

    And the stock is 40 cents? The historical low?

    What about GROWTH IN SALES? Factor that in? More likely BSDM will be pushing 20 million in sales than 10 million in fiscal 2015. IMHO.

    And also note that those contracts signed in China and Taiwan are 5 year deals. Those sales minimums repeat every year for 5 years. Also there is no debt in this company. Nothing. They do not owe one penny and do not need to service any debt. It will be very easy to turn the corner to profitablility now that BSD-2000's are starting to ship to Asia. Terumo will also be selling at a much higher rate this year as the MicroThermX ablation system gains traction in their 100 country territory.

    About Terumo Corporation

    A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology.

    And of course, one needs to add in U.S. sales of both hyperthermia and ablation devices. Those are not accounted for in the above numbers.

    Fiscal 2015 which began in September 2014, will be a record year in sales for BSDM, in my opinion. The facts all point directly to a record year.

  • As med tech companies set their sails toward China, a new trade agreement between the U.S. and Chinese governments looks to ease restrictions for imports, paving the way for greater expansion by U.S. devicemakers.
    China agreed to allow U.S. medical devices and medicines into local markets more quickly and to loosen up its antitrust procedures after bilateral trade talks between the two countries, saying it would "cut red tape for imports of new and innovative pharmaceuticals and medical devices and to deal with the backlog," U.S. Commerce Secretary Penny Pritzker said, as quoted by Reuters.
    Chinese officials also agreed to publish the results of administrative proceedings conducted under its antimonopoly laws and to allow U.S. firms to consult with legal counsel, Pritzker noted, a boon for devicemakers who have long criticized the country's trade laws for lacking transparency and unfairly targeting foreign companies.
    The news follows on the heels of another China win for med tech companies, as in November, the country's regulatory authority shortened its review process for imported medical devices and in vitro diagnostics under new regulators. Companies that fail to follow the guidelines will not have a second chance at submitting documentation if their application contains mistakes, but the new CFDA standards still bode well for devicemakers looking to expand in China.

  • canstic1 canstic1 Dec 11, 2014 5:06 PM Flag

    The deal with Orientech China, which is now approved by the China FDA is for sale of eight (8) BSD-2000's per year at a MINIMUM. They will most likely buy more. The deal to Taiwan calls for sale of 5 units per year MINIMUM, and they will most likely buy more. South Korea has a deal for another 5 per year, the approval in SK is still pending, and expected this year.

    We are now in the Q2 of fiscal year 2015 for BSDM. AT A MINIMUM, for this new fiscal year there will be 13 BSD-2000's sold, guaranteed to China(8) and Taiwan(5). BSDM has never sold 13 BSD-2000's in a single year , ever!

    These machines sell for $350,000 to over $1 million depending on how they are outfitted. That means at a minimum, and I stress MINIMUM, there will be $5 million in sales of BSD-2000's in fiscal year 2015.

    ADD in the sales of MicroThermX and replaceable antennas, and the MINIMUM sales I can possibly see occuring in fiscal 2015 is at least $10 million. BSDM has never had $10,000,000 in sales EVER

    And the stock is 40 cents? The historical low?

    What about GROWTH IN SALES? Factor that in? More likely BSDM will be pushing 20 million in sales than 10 million in fiscal 2015. IMHO.

    And also note that those contracts signed in China and Taiwan are 5 year deals. Those sales minimums repeat every year for 5 years. Also there is no debt in this company. Nothing. They do not owe one penny and do not need to service any debt. It will be very easy to turn the corner to profitablility now that BSD-2000's are starting to ship to Asia. Terumo will also be selling at a much higher rate this year as the MicroThermX ablation system gains traction in their 100 country territory.

    About Terumo Corporation

    A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology.

    And of course, one needs to add in U.S. sales of both hyperthermia and ablation devices. Those are not accounted for in the above numbers.

    Fiscal 2015 which began in September 2014, will be a record year in sales for BSDM, in my opinion. The facts all point directly to a record year.

  • canstic1 canstic1 Dec 8, 2014 8:48 AM Flag

    The deal with Orientech China, which is now approved by the China FDA is for sale of eight (8) BSD-2000's per year at a MINIMUM. They will most likely buy more. The deal to Taiwan calls for sale of 5 units per year MINIMUM, and they will most likely buy more. South Korea has a deal for another 5 per year, the approval in SK is still pending, and expected this year.

    We are now in the Q2 of fiscal year 2015 for BSDM. AT A MINIMUM, for this new fiscal year there will be 13 BSD-2000's sold, guaranteed to China(8) and Taiwan(5). BSDM has never sold 13 BSD-2000's in a single year , ever!

    These machines sell for $350,000 to over $1 million depending on how they are outfitted. That means at a minimum, and I stress MINIMUM, there will be $5 million in sales of BSD-2000's in fiscal year 2015.

    ADD in the sales of MicroThermX and replaceable antennas, and the MINIMUM sales I can possibly see occuring in fiscal 2015 is at least $10 million. BSDM has never had $10,000,000 in sales EVER

    And the stock is 40 cents? The historical low?

    What about GROWTH IN SALES? Factor that in? More likely BSDM will be pushing 20 million in sales than 10 million in fiscal 2015. IMHO.

    And also note that those contracts signed in China and Taiwan are 5 year deals. Those sales minimums repeat every year for 5 years. Also there is no debt in this company. Nothing. They do not owe one penny and do not need to service any debt. It will be very easy to turn the corner to profitablility now that BSD-2000's are starting to ship to Asia. Terumo will also be selling at a much higher rate this year as the MicroThermX ablation system gains traction in their 100 country territory.

    About Terumo Corporation

    A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology.

    And of course, one needs to add in U.S. sales of both hyperthermia and ablation devices. Those are not accounted for in the above numbers.

    Fiscal 2015 which began in September 2014, will be a record year in sales for BSDM, in my opinion. The facts all point directly to a record year.

LLY
70.59-0.06(-0.08%)Mar 5 4:01 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Geron Corporation
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orbital ATK, Inc.
NYSEThu, Mar 5, 2015 4:02 PM EST